pf-07038124
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Oct 23, 2019 (NCT04135560)
Timeline
Indications
Mechanism of action
- Phosphodiesterase 4AINHIBITOR
PDE4A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06013371 | Phase 2 | Jun 30, 2023 | Icahn School of Medicine at Mount Sinai, Pfizer |
| NCT05375955 | Phase 2 | Sep 26, 2022 | Pfizer |
| NCT05298033 | Phase 2 | Sep 7, 2022 | Pfizer, University of Colorado, Denver |
| NCT04863417 | Phase 1 | Jun 30, 2021 | Pfizer |
| NCT04664153 | Phase 2 | Dec 21, 2020 | Pfizer |
| NCT04135560 | Phase 1 | Oct 23, 2019 | Pfizer |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 6 | 4 | 2 | 2019 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Colorado, Denver | Academic/Hospital | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1